|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,748.00 GBX | +1.82% |
|
+3.14% | -0.30% |
| May. 12 | AstraZeneca's Phase 3 Trial Shows Significant Results in Patients With Hypoparathyroidism | MT |
| May. 12 | AstraZeneca hails phase-3 trial results for hypoparathyroidism drug | AN |
End-of-day quotes
Compared values
| Sector | Change | 5d. change | Varia. Jan 1. | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASTRAZENECA PLC | Other Pharmaceuticals | +1.82% | +3.14% | -0.30% | +33.84% | +76.57% | 286B |  | |  |
- Stock Market
- Equities
- AZN Stock
- Charts AstraZeneca PLC
- Relative Strength Chart
Select your edition
All financial news and data tailored to specific country editions
